Table 1.
PRMT5 inhibitor and their different mechanisms of action.
| Company | Compound | Trials | MOA | Ref. or Patent |
|---|---|---|---|---|
| GSK/Epizyme | GSK3326595 | Ph 1 NCT02783300Ph 2 NCT03614728 | b | [164] |
| Pfizer | PF-06939999 | Ph 1 NCT03854227 | a | [165] |
| Janssen | JNJ64619178 | Ph 1 NCT03573310 | c | AACR |
| Prelude | PRT543 | Ph 1 NCT03886831 | a | [166] |
| Prelude | PRT811 | Ph 1 NCT04089449 | a | [166] |
| Prelude | C449 | Pre-clinical | f | [167] |
| Eli Lilly | LLY-283 | Pre-clinical | a | [168] |
| Argonaut | T1-44 | Pre-clinical | b | [169] |
| Jian Jin | MS4322 | Pre-clinical | d | [159] |
| Merck | Comp 1A | Pre-clinical | e | [160] |
| Aurigene | AU-14755 | Pre-clinical | b | WO2019-180628 |
| Angex | Not named | Pre-clinical | a | WO2019-112719 |
| Jubilant | JPRMT5i | Pre-clinical | b | WO2019-102494 |
Mechanism of action (MOA): (a) SAM competitive; (b) SAM cooperative and peptide substrate competitive; (c) SAM and peptide substrate competitive; (d) PROTAC degrader; (e) allosteric modulator; and (f) covalent inhibitor. The “WO2019” numbers refer to patent submissions.